SCHEMBL31569482

SCHEMBL31569482

CC(C)(C)OC(=O)NCCc1nccc(Cl)c1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17B O94768 1/20 0.46
STK17A Q9UEE5 1/20 0.46
LMNA P02545 3/20 0.44
HPGD P15428 3/20 0.44
GAA P10253 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
TSHR P16473 2/20 0.43
ALDH1A1 P00352 4/20 0.42
HTT P42858 3/20 0.42
KDM4E B2RXH2 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPSR1 Q6W5P4 2/20 0.41
TP53 P04637 1/20 0.41
GLA P06280 1/20 0.41
MAPT P10636 1/20 0.41
XBP1 P17861 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PKM P14618 1/20 0.41
CA1 P00915 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15489631 0.82 LMNA (0.49) STK17BSTK17ALMNAHPGDGAA
SCHEMBL25056476 0.82 KDM4E (0.45) MEN1KMT2AALDH1A1HTTKDM4E
SCHEMBL15489572 0.79 ATR (0.45) STK17BSTK17ALMNAHPGDGAA
SCHEMBL16552184 0.79 STK17B (0.47) STK17BSTK17ALMNAHPGDGAA
SCHEMBL29967118 0.79 ATR (0.45) STK17BSTK17ALMNAHPGDGAA
SCHEMBL31569039 0.78 LMNA (0.42) STK17BSTK17ALMNAHPGDGAA
SCHEMBL5592422 0.76 NQO2 (0.47) ALDH1A1HTTKDM4ENPSR1CA1
SCHEMBL2129621 0.75 ALDH1A1 (0.49) STK17BSTK17ALMNAHPGDGAA
SCHEMBL6221982 0.75 STK17B (0.52) STK17BSTK17ALMNAHPGDGAA
SCHEMBL21455353 0.75 ATR (0.44) STK17BSTK17ALMNAHPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115174-A1 PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF OCTANT INC (US) 2026-04-30 US disclosed
WO-2025101780-A1 PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF OCTANT, INC. (US) 2025-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115174-A1 PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF PDE6D, PDE6H, ADRA1D STK17B 4562/4885STK17A 4601/4885LMNA 3152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.